About half of the American public has heard little or nothing about the new COVID-19 bivalent booster, a new survey by the Kaiser Family Foundation has found. The new booster Read more
Tag: Biotechnology
Global tally of COVID cases down 11% in latest week as fatalities fall 18%; BA.5 remains dominant strain
The global tally of COVID cases fell 11% in the week ending Sept. 25 from the week earlier, while the number of fatalities fell 18% to just over 8,900, the Read more
Global tally of COVID cases down 11% in latest week as fatalities fall 18%; BA.5 remains dominant strain
The global tally of COVID cases fell 11% in the week ending Sept. 25 from the week earlier, while the number of fatalities fell 18% to just over 8,900, the Read more
Stock of psychedelics company MindMed slides 50% after it sells fresh shares
Shares of psychedelics company Mind Medicine Inc. slid 50% Wednesday, after the company priced a dilutive secondary offering of 7.1 million shares. The offering was priced at $4.25 a share, Read more
U.S. and WHO commit to new fund for pandemic prevention and preparedness and urge world leaders to back it
The heads of the U.S. Department of Health and Human Services and the World Health Organization came away from the first U.S.-WHO Strategic Dialogue on Tuesday with a commitment to Read more
U.S. and WHO commit to new fund for pandemic prevention and preparedness and urge world leaders to back it
The heads of the U.S. Department of Health and Human Services and the World Health Organization came away from the first U.S.-WHO Strategic Dialogue on Tuesday with a commitment to Read more
Getting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive decline sent shares in both companies soaring, but some analysts are tempering their expectations until Read more
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late Tuesday lifted shares of Biogen Inc. BIIB, +1.04% to buy from neutral after the pharmaceutical Read more
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer’s disease drug significantly slowed progression of the disease in Read more
Alzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies Read more